Physician profile
Jacob Katz
NPI 1538387964
$4,245.00
in general payments reported to CMS, 2019-2025
16 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 92% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $295 · 2021: $648 · 2022: $513 · 2023: $602 · 2024: $639 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925 · Travel and Lodging: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.95 |
| Travel and Lodging | $739.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,618.53 | 2019-2025 | |
| Pacira Pharmaceuticals Incorporated | $1,225.07 | 2023-2025 | Iovera, Zilretta |
| Amgen INC. | $687.71 | 2021-2025 | Enbrel, Otezla, Otezla |
| Horizon Therapeutics Plc | $209.15 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $125.03 | 2024 | Envista Mx60 Iol |
| Janssen Biotech, INC. | $94.21 | 2023-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $48.41 | 2021 | |
| Glaxosmithkline, LLC. | $42.94 | 2022-2024 | Benlysta |
| Novo Nordisk INC | $33.39 | 2022-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $31.76 | 2023 | |
| Bioventus LLC | $29.64 | 2020 | |
| Ani Pharmaceuticals, INC. | $28.93 | 2025 | Purified Cortrophin Gel |
| Pacira Therapeutics, INC. | $20.26 | 2021 | |
| Depuy Synthes Sales INC. | $17.89 | 2024 | Orthovisc |
| Lilly USA, LLC | $16.59 | 2025 | Zepbound |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.